Evidence map›Paper›PMID 34690973›Full record

ArticleFrontiers in microbiology2021

Increased Frequency of Inter-Subtype HIV-1 Recombinants Identified by Near Full-Length Virus Sequencing in Rwandan Acute Transmission Cohorts.

Gisele Umviligihozo, Erick Muok, Emmanuel Nyirimihigo Gisa, Rui Xu, Dario Dilernia, Kimberley Herard, Heeyah Song, Qianhong Qin, Jean Bizimana, Paul Farmer and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Gisele UmviligihozoCentre for Family Health Research, Kigali, Rwanda.
Erick MuokCentre for Family Health Research, Kigali, Rwanda.
Emmanuel Nyirimihigo GisaCentre for Family Health Research, Kigali, Rwanda.
Rui XuEmory Vaccine Center at Yerkes National Primate Research Center, Atlanta, GA, United States.
Dario DilerniaEmory Vaccine Center at Yerkes National Primate Research Center, Atlanta, GA, United States.
Kimberley HerardEmory Vaccine Center at Yerkes National Primate Research Center, Atlanta, GA, United States.
Heeyah SongEmory Vaccine Center at Yerkes National Primate Research Center, Atlanta, GA, United States.
Qianhong QinEmory Vaccine Center at Yerkes National Primate Research Center, Atlanta, GA, United States.
Jean BizimanaCentre for Family Health Research, Kigali, Rwanda.
Paul FarmerEmory Vaccine Center at Yerkes National Primate Research Center, Atlanta, GA, United States.
Jonathan HareIAVI, New York, NY, United States.
Jill GilmourFaculty of Medicine, Imperial College London, London, United Kingdom.
Susan AllenDepartment of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, United States.
Etienne KaritaCentre for Family Health Research, Kigali, Rwanda.
Eric HunterEmory Vaccine Center at Yerkes National Primate Research Center, Atlanta, GA, United States.
Ling YueEmory Vaccine Center at Yerkes National Primate Research Center, Atlanta, GA, United States.
Emory National Primate Research CenterEmory University · USImperial College London · GBInternational AIDS Vaccine Initiative · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Virologic Correlates of Heterosexual TransmissionR01AI051231 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ALLEN, TODD M, HUNTER, ERIC · 2002 to 2022
$9.9M
Deciphering the impact of sex in early subtype C HIV infection and during HARTR01AI172740 · NIAID · EMORY UNIVERSITY · PI Eric Hunter · 2022 to 2026
$4.3M
NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI051231NIAID NIH HHS R01 AI172740NIH HHS P51 OD011132
6 · The paper itself

Abstract

Most studies of HIV-1 transmission have focused on subtypes B and C. In this study, we determined the genomic sequences of the transmitted founder (TF) viruses from acutely infected individuals enrolled between 2005 and 2011 into IAVI protocol C in Rwanda and have compared these isolates to viruses from more recent (2016-2019) acute/early infections in three at risk populations - MSM, high risk women (HRW), and discordant couples (DC). For the Protocol C samples, we utilized near full-length single genome (NFLG) amplification to generate 288 HIV-1 amplicons from 26 acutely infected seroconverters (SC), while for the 21 recent seroconverter samples (13 from HRW, two from DC, and six from MSM), we PCR amplified overlapping half-genomes. Using PacBio SMRT technology combined with the MDPseq workflow, we performed multiplex sequencing to obtain high accuracy sequences for each amplicon. Phylogenetic analyses indicated that the majority of recent transmitted viruses from DC and HRW clustered within those of the earlier Protocol C cohort. However, five of six sequences from the MSM cohort branched together and were greater than 97% identical. Recombination analyses revealed a high frequency (6/26; 23%) of unique inter-subtype recombination in Protocol C with 19% AC and 4% CD recombinant viruses, which contrasted with only 6.5% of recombinants defined by sequencing of the

Indexed as

antiretroviral drug resistance mutationsgenetic bottleneckHIV-1 transmissionHIV subtypeinter-subtype recombinationnear full-length genome sequencing

Identifiers

PMID34690973
PMCPMC8529237
OpenAlexW3206764589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.